{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Novartis India Ltd
Novartis India Gains 4.90%: 5 Key Factors Driving the Week’s Momentum
Novartis India Ltd delivered a strong weekly performance, rising 4.90% from Rs.1,570.30 to Rs.1,647.25 between 20 and 24 July 2026, significantly outperforming the Sensex which declined 1.85% over the same period. The stock’s rally was marked by a new 52-week and all-time high on 23 July, supported by robust quarterly results, an upgrade in quality grade, and improved financial trends, despite some profit margin pressures and short-term volatility.
Are Novartis India Ltd latest results good or bad?
Novartis India Ltd's Q1 FY27 results are positive, showing an 18.57% increase in net sales to ₹103.81 crores and a 16.62% rise in net profit to ₹32.21 crores, alongside improved operating margins and a strong balance sheet, indicating robust operational recovery and growth potential.
Novartis India Ltd Reports Strong Quarterly Turnaround with Robust Revenue and Margin Expansion
Novartis India Ltd has demonstrated a remarkable financial turnaround in the quarter ended June 2026, shifting from a negative trend to a positive trajectory with record-breaking revenue and profit metrics. This resurgence is underscored by significant margin expansion and operational efficiency gains, positioning the small-cap pharmaceutical player favourably against its historical performance and broader market benchmarks.
Novartis India Q1 FY27: Strong Profit Surge Masks Valuation Concerns
Novartis India Ltd. (NSE: NOVARTIND), the domestic subsidiary of Swiss pharmaceutical giant Novartis AG, posted a robust performance in Q1 FY27 (June 2026 quarter), with net profit surging 27.56% quarter-on-quarter to ₹32.21 crores, marking its highest quarterly profit in recent periods. However, the stock retreated 1.77% following the results announcement, as investors grappled with premium valuation concerns despite the strong operational performance.
Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1777.5
Novartis India Ltd has reached a significant milestone by touching a new 52-week high of Rs.1777.5 on 23 Jul 2026, marking a notable achievement in its stock performance amid a volatile market environment.
Novartis India Ltd Hits All-Time High of Rs 1,745 as Momentum Builds Across Timeframes
Extending its remarkable rally, Novartis India Ltd touched a fresh all-time high of Rs 1,745 on 23 Jul 2026, marking a significant milestone in its recent price trajectory.
Novartis India Ltd Upgrades Quality Grade Amid Strong Financial Fundamentals
Novartis India Ltd has seen its quality grade upgraded from average to good, reflecting notable improvements in its business fundamentals. Despite a modest decline in sales growth over five years, the company’s robust profitability, conservative debt levels, and strong returns on capital have underpinned this positive reassessment, positioning it favourably within the Pharmaceuticals & Biotechnology sector.
Novartis India Ltd Gains 5.33%: 5 Key Factors Driving the Week’s Momentum
Novartis India Ltd delivered a solid weekly gain of 5.33%, closing at Rs.1,570.30 on 17 July 2026, outperforming the Sensex which remained flat over the same period. The stock demonstrated strong intraday and closing highs early in the week, reaching new 52-week and all-time highs before consolidating in the latter sessions amid mixed market conditions. This review analyses the key events and price movements that shaped the stock’s performance during the week of 13 to 17 July 2026.
Novartis India Ltd is Rated Hold
Novartis India Ltd is rated Hold by MarketsMOJO, with this rating last updated on 11 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 July 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1711.05
With a 60.75% gain over the past year, Novartis India Ltd has surged to a fresh 52-week high of Rs 1711.05 on 14 Jul 2026, outpacing the Sensex which declined 6.21% over the same period. This rally is underpinned by a confluence of bullish technical indicators and sustained price momentum, marking a significant milestone for the pharmaceuticals & biotechnology small-cap.
Novartis India Ltd Hits All-Time High of Rs 1711.05 as Momentum Builds Across Timeframes
Novartis India Ltd has reached a significant milestone, touching an all-time high price of Rs.1711.05 on 14 July 2026, marking a remarkable phase in the company’s stock performance within the Pharmaceuticals & Biotechnology sector.
Novartis India Ltd Surges 10.79% to New 52-Week High — Outperforms Sector by 8.33 Percentage Points
The Sensex declined by 0.38% on 13 Jul 2026, while Novartis India Ltd surged 10.79%, marking a standout session in the Pharmaceuticals & Biotechnology sector with an 8.33 percentage-point outperformance. This sharp intraday gain propelled the stock to a new 52-week and all-time high of Rs 1,629.9, rewriting the short-term narrative for this small-cap player.
Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1599
Surging past its previous peaks, Novartis India Ltd touched a fresh 52-week high of Rs 1599 on 13 Jul 2026, marking a remarkable 113.2% rise from its 52-week low of Rs 750. This milestone comes amid a sustained rally fuelled by a confluence of bullish technical indicators and strong price momentum, even as the broader Sensex trades lower.
Strong Momentum Meets Stretched Valuations as Novartis India Ltd Reaches All-Time High
Novartis India Ltd has reached a significant milestone by touching its all-time high price of Rs 1,588.40 on 13 Jul 2026, reflecting a robust performance in the Pharmaceuticals & Biotechnology sector and marking a notable achievement for the small-cap company.
When is the next results date for Novartis India Ltd?
The next results date for Novartis India Ltd is July 23, 2026.
Novartis India Ltd is Rated Hold
Novartis India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Novartis India Ltd is Rated Hold
Novartis India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Novartis India Ltd Surges 7.06% to Day's High of Rs 1470 — Outperforms Sector by 5.73 Percentage Points
The Sensex advanced 0.57% on 22 Jun 2026, while Novartis India Ltd surged 7.06%, touching an intraday high of Rs 1470. This 5.73-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.
Novartis India Ltd Falls 10.71%: 3 Key Factors Driving the Weekly Decline
Novartis India Ltd experienced a challenging week from 1 to 5 June 2026, with its share price declining 10.71% to close at Rs.1,388.90, significantly underperforming the Sensex which fell 0.78% over the same period. Despite hitting a new 52-week and all-time high of Rs.1,588.40 on 1 June, the stock faced sustained selling pressure midweek before modest recovery attempts on the final two trading days.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
